Is intranasal vaccination a feasible solution for tuberculosis?

References

• World Health Organization. Global tuberculosis control: surveillance, planning financing. WHO/HTM/TB/2005. WHO Report. Geneva, Switzerland (2005).
   Google Scholar
• World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TB/2008.393. WHO Report. Geneva, Switzerland (2008).
   Google Scholar
• World Health Organization. 2007 tuberculosis facts. WHO Report. Geneva, Switzerland (2008).
   Google Scholar
• Frothingham R, Stout JE, Hamilton CD. Current issues in global tuberculosis control. Int. J. Infect. Dis.9(6), 297–311 (2005).
   PubMed Web of Science ®Google Scholar
• Flynn JL, Chan J. Immunology of tuberculosis. Annu. Rev. Immunol.19, 93–129 (2001).
   PubMed Web of Science ®Google Scholar
• Wolf AJ, Desvignes L, Linas B et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J. Exp. Med.205(1), 105–115 (2008).
   PubMed Web of Science ®Google Scholar
• Wolf AJ, Linas B, Trevejo-Nuñez GJ et al.Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J. Immunol.179(4), 2509–2519 (2007).
   PubMed Web of Science ®Google Scholar
• Geijtenbeek T, Van Vliet SJ, Koppel EA et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J. Exp. Med.197(1), 7–17 (2003).
   PubMed Web of Science ®Google Scholar
• Schorey JS, Lawrence C. The pattern recognition receptor dectin-1: from fungi to mycobacteria. Curr. Drug Targets9(2), 123–129 (2008).
   PubMedGoogle Scholar
• Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell111(1), 927–930 (2002).
   PubMed Web of Science ®Google Scholar
• Mogensen TH, Paludan SR. Reading the viral signature by Toll-like receptors and other pattern recognition receptors. J. Mol. Med.83(1), 180–192 (2005).
   PubMed Web of Science ®Google Scholar
• Torrelles JB, Azad AK, Henning LN, Carlson TK, Schlesinger LS. Role of C-type lectins in mycobacterial infections.Curr. Drug Targets9(2), 102–112 (2008).
   PubMedGoogle Scholar
• Quesniaux VJ, Nicolle DM, Torres D et al. Toll-like receptor 2 (TLR2)-dependent-positive and TLR2-independent-negative regulation of proinflammatory cytokines by mycobacterial lipomannans. J. Immunol.172(7), 4425–4434 (2004).
   PubMed Web of Science ®Google Scholar
• Jones BW, TK Means, KA Heldwein et al. Different Toll-like receptor agonists induce distinct macrophage responses. J. Leukocyte Biol.69(6), 1036–1044 (2001).
   PubMedGoogle Scholar
• Gilleron M, Quesniaux VF, Puzo G. Acylation state of the phosphatidyl inositol hexamannosides from Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Rv and its implication in TLR response. J. Biol. Chem.278(32), 29880–29889 (2003).
   PubMedGoogle Scholar
• Noss EH, Pai RK, Sellati TJ et al. Toll-like receptor 2-dependent inhibition of macrophage class II MHC expression and antigen processing by 19 kD lipoprotein of Mycobacterium tuberculosis. J. Immunol.167(2), 910–918 (2001).
   PubMed Web of Science ®Google Scholar
• Pai RK, M Convery, Hamilton TA, Boom WH, Harding CV. Inhibition of IFN-γ-induced class II transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion. J. Immunol.171(1), 175–184 (2003).
   PubMed Web of Science ®Google Scholar
• Brightbill HD, Libraty DH, Krutzik SR et al. Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors. Science285(5428), 732–736 (1999).
   PubMed Web of Science ®Google Scholar
• Gehring AJ, Dobos KM, Belisle JT, Harding CV, Boom WH. Mycobacterium tuberculosis LprG (Rv1411c): a novel TLR-2 ligand that inhibits human macrophage class II MHC antigen processing. J. Immunol.173(4), 2660–2668 (2004).
   PubMed Web of Science ®Google Scholar
• Pecora ND, Gehring AJ, Canaday DH, Boom WH, Harding CV. Mycobacterium tuberculosis LprA is a lipoprotein agonist of TLR2 that regulates innate immunity and APC function. J. Immunol.177(1), 422–429 (2006).
   PubMed Web of Science ®Google Scholar
• Gatfield J, Pieters J. Essential role for cholesterol in entry of mycobacteria into macrophages. Science288(5471), 1647–1650 (2000).
   PubMed Web of Science ®Google Scholar
• Ferrari G, Langen H, Naito M, Pieters J. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell97(4), 435–447 (1999).
   PubMed Web of Science ®Google Scholar
• Jayachandran R, Sundaramurthy V, Combaluzier B et al. Survival of mycobacteria in macrophages is mediated by coronin 1-dependent activation of calcineurin. Cell130(1), 37–50 (2007).
   PubMed Web of Science ®Google Scholar
• Russel DG, Dant J, Sturgill-Kaszycki S. Mycobacterium avium and Mycobacterium tuberculosis containing vacuoles are dynamic, fusion competent vesicles that are accessible to glycosphingolipids from the host cell plasmalemma. J. Immunol.156(12), 4764–4773 (1996).
   PubMedGoogle Scholar
• Schaible UE, Sturgill-Koszycki S, Schlesinger PH, Russell DG. Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages. J. Immunol.160(3), 1290–1296 (1998).
   PubMed Web of Science ®Google Scholar
• Collins HL, Kaufman SHE. The many faces of the host response to tuberculosis. Immunology103(1), 1–9 (2001).
   PubMed Web of Science ®Google Scholar
• Manca C, Paul S, Barry CE, Freedman VH, Kaplan G. Mycobacterium tuberculosis catalase and peroxidase activities and resistance to oxidative killing in human monocytes in vitro. Infect. Immun.67(1), 74–79 (1999).
   PubMed Web of Science ®Google Scholar
• Master SS, Rampini SK, Davis AS et al.Mycobacterium tuberculosis prevents inflammasome activation. Cell Host Microbe3(4), 224–232 (2008).
   PubMed Web of Science ®Google Scholar
• North RJ, Ryan L, LaCource R, Mogues T, Goodrich ME. Growth rate of mycobacteria in mice as an unreliable indicator of mycobacterial virulence. Infect. Immun.67(10), 5483–5485 (1999).
   PubMed Web of Science ®Google Scholar
• Manca C, Tsenova L, Barry CE et al.Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J. Immunol.162(11), 6740–6746 (1999).
   PubMed Web of Science ®Google Scholar
• Manca C, Tsenova L, Bergtold A et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β. Proc. Natl Acad. Sci. USA98(10), 5752–5757 (2001).
   PubMed Web of Science ®Google Scholar
• Reed MB, Domenech P, Manca C et al. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature431(7004), 84–87 (2004).
   PubMed Web of Science ®Google Scholar
• Newton SM, Smith RJ, Wilkinson KA et al. A deletion defining a common Asian lineage of Mycobacterium tuberculosis associates with immune subversion. Proc. Natl Acad. Sci. USA103(42), 15594–15598 (2006).
   PubMedGoogle Scholar
• Dao DN, Kremer L, Guérardel Y et al.Mycobacterium tuberculosis lipomannan induces apoptosis and interleukin-12 production in macrophages. Infect. Immun.72(4), 2067–2074 (2004).
   PubMedGoogle Scholar
• Neill MA, Klebanoff SJ. The effect of phenolic glycolipid-I from Mycobacterium leprae on the antimicrobial activity of human macrophages. J. Exp. Med.167(1), 30–42 (1988).
   PubMed Web of Science ®Google Scholar
• Russell DG. Who puts the tubercle in tuberculosis? Nat. Rev. Microbiol.5(1), 39–47 (2007).
   PubMed Web of Science ®Google Scholar
• Hart PD, Armstrong JA, Brown CA, Draper P. Ultrastructural study of the behavior of macrophages toward parasitic mycobacteria. Infect. Immun.5(5), 803–807 (1972).
   PubMed Web of Science ®Google Scholar
• Armstrong JA, Hart PD. Phagosome–lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival. J. Exp. Med.142(1), 1–16 (1975).
   PubMed Web of Science ®Google Scholar
• Russell DG. Mycobacterium tuberculosis: here today, and here tomorrow. Nat. Rev. Mol. Cell Biol.2(1), 569–577 (2001).
   PubMed Web of Science ®Google Scholar
• van der Wel N, Hava D, Houben D et al.M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell129(7), 1287–1298 (2007).
   PubMed Web of Science ®Google Scholar
• Kaufamann SHE. How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol.1(1), 20–30 (2001).
   PubMed Web of Science ®Google Scholar
• McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxate shunt enzme isocitrate lyase. Nature406(6797), 735–738 (2000).
   PubMed Web of Science ®Google Scholar
• Weber I, Fritz C, Ruttkowski, Kreft A, Bange FC. Anaerobic nitrate reductase (narGH JI) activity of Mycobacterium bovis BCG in vitro and its contribution to virulence in immunodeficient mice. Mol. Microbiol.35(5), 1017–1025 (2000).
   PubMedGoogle Scholar
• Behr MA, Small PM. A historical and molecular phylogeny of BCG strains. Vaccine17(7–8), 915–922 (1999).
   PubMed Web of Science ®Google Scholar
• Fine PE. The BCG story: lessons from the past and implications for the future. Rev. Infect. Dis.11(2), S353–359 (1989).
   PubMedGoogle Scholar
• Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet346(8986), 1339–1345 (1995).
   PubMed Web of Science ®Google Scholar
• Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA271(9), 698–702 (1994).
   PubMed Web of Science ®Google Scholar
• Tuberculosis Research Center (ICMR), Chennai. Fifteen year follow up of trial of BCG South India for tuberculosis prevention. Indian J. Med. Res.110(1), 56–69 (1999).
   PubMed Web of Science ®Google Scholar
• Aronson NE, Santosham M, Comstock GW et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA291(17), 2086–2091 (2004).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Issues relating to the use of BCG in immunization programmes. WHO/V&B/99.23. WHO Report. Geneva, Switzerland (1999)
   Google Scholar
• Brewer TF, Colditz GA. Relationship between bacille Calmette–Guérin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Clin. Infect. Dis.20(1), 126–135 (1995).
   PubMed Web of Science ®Google Scholar
• Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon-γ in resistance to Mycobacterium tuberculosis infection. J. Exp. Med.178(6), 2249–2254 (1993).
   PubMed Web of Science ®Google Scholar
• Cooper AM, Dalton DK, Stewart TA, Griffen JP, Russell DG, Orme IM. Disseminated tuberculosis in IFN-γ gene-disrupted mice. J. Exp. Med.178(6), 2243–2247 (1993).
   PubMed Web of Science ®Google Scholar
• Cooper AM, Magram J, Ferrante J, Orme IM. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J. Exp. Med.186(1), 39–45 (1997).
   PubMed Web of Science ®Google Scholar
• Jung Y-J, LaCourse R, Ryan L, North RJ. Evidence inconsistent with a negative influence of T helper 2 cells on protection afforded by a dominant T helper 1 response against Mycobacterium tuberculosis lung infection in mice. Infect. Immun.70(11), 6436–6443 (2002).
   PubMedGoogle Scholar
• Agger EM, Andersen P. Tuberculosis subunit vaccine development: on the role of interferon-γ. Vaccine19(17–19), 2298–2302 (2001).
   PubMed Web of Science ®Google Scholar
• Vekemans J, Lienhardt C, Sillah JS et al. Tuberculosis contacts but not patients have higher γ interferon responses to ESAT-6 than do community controls in The Gambia. Infect. Immun.69(10), 6554–6557 (2001).
   PubMedGoogle Scholar
• Elias D, Akuffo H, Pawlowski A, Haile M, Schon T, Britton S. Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis. Vaccine23(11), 1326–1334 (2005).
   PubMed Web of Science ®Google Scholar
• Malhotra I, Mungai P, Wamachi A et al. Helminth- and bacillus Calmette–Guerin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. J. Immunol.162(1), 6843–6848 (1999).
   PubMed Web of Science ®Google Scholar
• Elias D, Wolday D, Akuffo H, Petros B, Bronner U, Britton S. Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette–Guerin (BCG) vaccination. Clin. Exp. Immunol.123(2), 219–225 (2001).
   PubMed Web of Science ®Google Scholar
• Colditz GA, TF Brewer, CS Berkey, ME Wilson, E Burdick, HV Fineberg et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA271, 698–702 (1994).
   PubMed Web of Science ®Google Scholar
• Giri PK, Sable SB, Verma I, Khuller GK. Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis. FEMS Immunol. Med. Microbiol.45(1), 87–93 (2005).
   PubMedGoogle Scholar
• Giri PK, Verma I, Khuller GK. Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. J. Infect.53(5), 350–356 (2006).
   PubMed Web of Science ®Google Scholar
• Giri PK, Verma I, Khuller GK. Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal administration. FEMS Immunol. Med. Microbiol.47(2), 233–241 (2006).
   PubMed Web of Science ®Google Scholar
• Källenius G, Pawlowski A, Brandtzaeg P, Svenson S. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis87(4), 257–266 (2007).
   PubMed Web of Science ®Google Scholar
• Andersen CS, Dietrich J, Agger EM, Lycke NY, Lövgren K, Andersen P. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect. Immun.75(1), 408–416 (2007).
   PubMed Web of Science ®Google Scholar
• Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette–Guerin immunity. J. Immunol.177(9), 6353–6360 (2006).
   PubMed Web of Science ®Google Scholar
• Wang J, Thorson L, Stokes RW et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol.173(10), 6357–6365 (2004).
   PubMed Web of Science ®Google Scholar
• Chen L, Wang J, Zganiacz A, Xing Z. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared with subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun.72(1), 238–246 (2004).
   PubMed Web of Science ®Google Scholar
• Ogra PL. Mucosal immunoprophylaxis: an introductory overview. In: Mucosal Vaccines. Russell MW, Martin MH, Wu HY, Hollingshead SK (Eds). Academic Press, London, UK 3–14 (1996).
   Google Scholar
• Davis SS. Nasal vaccines. Adv. Drug. Deliv. Rev.51(1–3), 21–42 (2001).
   PubMed Web of Science ®Google Scholar
• Rudin A, Johansson EL, Bergquist C, Holmgren J. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect Immun.66(7), 3390–3396 (1998).
   PubMed Web of Science ®Google Scholar
• Andersen P, Doherty TM. The success and failure of BCG– implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol.3(8), 656–662 (2005).
   PubMed Web of Science ®Google Scholar
• Glueck R. Review of intranasal influenza vaccine. Adv. Drug Deliv. Rev.51(1–3), 203–211 (2001).
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine25(30), 5467–5484 (2007).
   PubMed Web of Science ®Google Scholar
• Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J. Exp. Med.184(5), 1879–1890 (1996).
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Moss B, Strober W, Berzofsky JA. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by pre existing poxvirus immunity. Proc. Natl Acad. Sci. USA96(8), 4512–4517 (1999).
   PubMed Web of Science ®Google Scholar
• Flesch IE, Kaufmann SH. Attempts to characterize the mechanisms involved in mycobacterial growth inhibition by γ-interferon-activated bone marrow macrophages. Infect. Immun.56(6), 1464–1469 (1988).
   PubMed Web of Science ®Google Scholar
• Behar SM, Woodworth JS, Wu Y. Next generation: tuberculosis vaccines that elicit protective CD8+ T cells. Expert Rev. Vaccines6(3), 441–456 (2007).
   PubMed Web of Science ®Google Scholar
• Woodworth JS, Behar SM. Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity. Crit. Rev. Immunol.26(4), 317–352 (2006).
   PubMed Web of Science ®Google Scholar
• Boom WH, Chervenak KA, Mincek MA, Ellner JJ. Role of the mononuclear phagocyte as an antigen-presenting cell for human γ δ T cells activated by live Mycobacterium tuberculosis. Infect. Immun.60(9), 3480–3488 (1992).
   PubMed Web of Science ®Google Scholar
• Boom WH. γδ T cells and Mycobacterium tuberculosis. Microbes Infect.1(3), 187–195 (1999).
   PubMed Web of Science ®Google Scholar
• Porcelli SA, Hämmerling G. Antigen processing and recognition. Curr. Opin. Immunol.18(1), 61–63 (2006).
   PubMedGoogle Scholar
• Chackerian A, Alt J, Perera V, Behar SM. Activation of NKT cells protects mice from tuberculosis. Infect. Immun.70(11), 6302–6309 (2002).
   PubMed Web of Science ®Google Scholar
• Gumperz JE, Brenner MB. CD1-specific T cells in microbial immunity. Curr. Opin. Immunol.13(4), 471–478 (2001).
   PubMedGoogle Scholar
• Santosuosso M, Zhang X, McCormick S, Wang J, Hitt M, Xing Z. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J. Immunol.174(12), 7986–7994 (2005).
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Tjarnlund A, Ivanji J et al. Role of IgA in the defense against respiratory infections IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG. Vaccine23(20), 2565–2572 (2005).
   PubMed Web of Science ®Google Scholar
• Williams A, Reljic R, Naylor I et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology111(3), 328–333 (2004).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Juarrero M, Orme IM. Characterization of murine lung dendritic cells infected with Mycobacterium tuberculosis. Infect. Immun.69, 1127–1133 (2001).
   PubMedGoogle Scholar
• González-Juarrero M, Turner J, Basaraba RJ, Belisle JT, Orme IM. Florid pulmonary inflammatory responses in mice vaccinated with antigen-85 pulsed dendritic cells and challenged by aerosol with Mycobacterium tuberculosis. Cell. Immunol.220(1), 13–19 (2002).
   PubMed Web of Science ®Google Scholar
• Kunkel EJ, Campbell DJ, Butcher EC. Chemokines in lymphocyte trafficking and intestinal immunity. Microcirculation10(3–4), 313–323 (2003).
   PubMed Web of Science ®Google Scholar
• Mora JR, Bono MR, Manjunath N et al. Selective imprinting of gut-homing T cells by Peyer’s patch dendritic cells. Nature424(6944), 88–93 (2003).
   PubMed Web of Science ®Google Scholar
• Stagg AJ, Kamm MA, Knight SC. Intestinal dendritic cells increase T cell expression of α4β7 integrin. Eur. J. Immunol.32(5), 1445–1454 (2002).
   PubMed Web of Science ®Google Scholar
• Vajdy M, O’Hagan DT. Microparticles for intranasal immunization. Adv. Drug Del. Rev.51(1), 127–141 (2001).
   PubMed Web of Science ®Google Scholar
• Vajdy M, Singh M. The role of adjuvants in the development of mucosal vaccines. Expert Opin. Biol. Ther.5(7), 953–965 (2005).
   PubMed Web of Science ®Google Scholar
• Wong YL, Sampson S, Germishuizen WA et al. Drying a tuberculosis vaccine without freezing. Proc. Natl Acad. Sci USA104(8), 2591–2595 (2007).
   PubMed Web of Science ®Google Scholar
• Bivas-Benita M, van Meijgaarden KE, Franken KL et al. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine22(13–14), 1609–1615 (2004).
   PubMed Web of Science ®Google Scholar
• Brun P, Zumbo A, Castagliuolo I et al. Intranasal delivery of DNA encoding antigens of Mycobacterium tuberculosis by non-pathogenic invasive Escherichia coli.Vaccine26(16), 1934–1941 (2008).
   PubMed Web of Science ®Google Scholar
• Lyadova IV, Vordermeier HM, Eruslanov EB, Khaidukov SV, Apt AS, Hewinson RG. Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-γ in their lungs. Clin. Exp. Immunol.126(2), 274–279 (2001).
   PubMedGoogle Scholar
• Tree JA, Williams A, Clark S, Hall G, Marsh PD, Ivanyi J. Intranasal bacille Calmette–Guerin (BCG) vaccine dosage needs balancing between protection and lung pathology. Clin. Exp. Immunol.138(3), 405–409 (2004).
   PubMedGoogle Scholar
• Haile M, Hamasur B, Jaxmar T et al. Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice. Tuberculosis (Edinb).85(1–2), 107–114 (2005).
   PubMed Web of Science ®Google Scholar
• Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette–Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol.171(3), 1602–1609 (2003).
   PubMed Web of Science ®Google Scholar
• Gonçalves ED, Bonato VL, da Fonseca DM et al. Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming. Genet. Vaccines Ther.5, 7 (2007).
   PubMedGoogle Scholar
• Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun.74(8), 4634–4643 (2006).
   PubMed Web of Science ®Google Scholar
• Sereinig S, Stukova M, Zabolotnyh N et al. Influenza virus NS vectors expressing the Mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge. Clin. Vaccine Immunol.13(8), 898–904 (2006).
   PubMed Web of Science ®Google Scholar
• Murphy TV, Gargiullo PM, Massoudi MS et al. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med.344(8), 564–572 (2001).
   PubMed Web of Science ®Google Scholar
• Cox E, Verdonck F, Vanrompay D, Goddeeris B. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet. Res.37(3), 511–539 (2006).
   PubMed Web of Science ®Google Scholar
• Freytag LC, Clements JD. Mucosal adjuvants. Vaccine23(15), 804–813 (2005).
   Google Scholar
• O’Hagan DT, MacKichan ML, Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol. Eng.18(3), 69–85 (2001).
   PubMedGoogle Scholar
• Giuliani MM, Del Giudice G, Giannelli V et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med.187(7), 1123–1132 (1998).
   PubMed Web of Science ®Google Scholar
• Takahashi H, Sasaki K, Takahashi M et al. Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+ T cells to nasal killed-bacillus Calmette–Guerin in mice. Vaccine24(17), 3591–3598 (2006).
   PubMed Web of Science ®Google Scholar
• Jakobsen H, Schulz D, Pizza M, Rappuoli R, Jonsdottir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as ajuvants rotects mice against invasive pneumococcal infections. Infect. Immun.67(11), 5892–5897 (1999).
   PubMed Web of Science ®Google Scholar
• Ryan EJ, McNeela E, Murphy GA et al. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun.67(12), 6270–6280 (1999).
   PubMed Web of Science ®Google Scholar
• Sun JB, Mielcarek N, Lakew M et al. Intranasal administration of a Schistosoma mansoni glutathione S-transferase–cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice. J. Immunol.163(2), 1045–1052 (1999).
   PubMed Web of Science ®Google Scholar
• Peppoloni S, Ruggiero P, Contorni M et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert. Rev. Vaccines2(2), 285–293 (2003).
   PubMedGoogle Scholar
• Rodriguez A, Troye-Blomberg M, Lindroth K, Ivanyi J, Singh M, Fernandez C. B- and T-cell responses to the mycobacterium surface antigen PstS-1 in the respiratory tract and adjacent tissues. Role of adjuvants and routes of immunization. Vaccine21(5–6), 458–467 (2003).
   PubMed Web of Science ®Google Scholar
• Salkowski CA, Detore GR, Vogel SN. Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, γ interferon, and interleukin-10 mRNA production in murine macrophages. Infect. Immun.65(8), 3239–3247 (1997).
   PubMed Web of Science ®Google Scholar
• Moore A, McCarthy L, Mills KH. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine17(20–21), 2517–2527 (1999).
   PubMed Web of Science ®Google Scholar
• Baldridge JR, Yorgensen Y, Ward JR, Ulrich JT. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine18(22), 2416–2425 (2000).
   PubMed Web of Science ®Google Scholar
• Childers NK, Miller KL, Tong G et al. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. Infect. Immun.68(10), 5509–5516 (2000).
   PubMed Web of Science ®Google Scholar
• Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol.6(1), 495–524 (1995).
   PubMedGoogle Scholar
• Johnson DA, Keegan DS, Sowell CG et al. 3-O-desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities. J. Med. Chem.42(22), 4640–4649 (1999).
   PubMed Web of Science ®Google Scholar
• Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature374(6522), 546–549 (1995).
   PubMed Web of Science ®Google Scholar
• von Meyenn F, Schaefer M, Weighardt H et al. Toll-like receptor 9 contributes to recognition of Mycobacterium bovis bacillus Calmette–Guérin by Flt3-ligand generated dendritic cells. Immunobiology211(6–8), 557–565 (2006).
   PubMedGoogle Scholar
• Klinman DM. CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine. Expert Rev. Vaccines5(3), 365–369 (2006).
   PubMed Web of Science ®Google Scholar
• Kerkmann M, Lochmann D, Weyermann J et al. Immunostimulatory properties of CpG-oligonucleotides are enhanced by the use of protamine nanoparticles. Oligonucleotides16(4), 313–322 (2006).
   PubMedGoogle Scholar
• Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. Adv. Drug. Deliv. Rev.60(7), 795–804 (2008).
   PubMed Web of Science ®Google Scholar
• Cox E, Verdonck F, Vanrompay D et al. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet. Res.37(3), 511–539 (2006).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Adamsson J, Anjuère F et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol. Lett.97(2), 181–188 (2005).
   PubMed Web of Science ®Google Scholar
• Juffermans NP, Leemans JC, Florquin S et al. CpG oligodeoxynucleotides enhance host defense during murine tuberculosis. Infect. Immun.70(1), 147–152 (2002).
   PubMed Web of Science ®Google Scholar
• Doherty TM, Dietrich J, Billeskov R. Tuberculosis subunit vaccines: from basic science to clinical testing. Expert Opin. Biol. Ther.7(10), 1539–1549 (2007).
   PubMed Web of Science ®Google Scholar
• Gall D. The adjuvant activity of aliphatic nitrogenous bases. Immunology11(4), 369–386 (1966).
   PubMed Web of Science ®Google Scholar
• Katz D, Kraaijeveld CA, Snippe H. Synthetic lipoid compounds as antigen-specific immunostimulators for improving the efficacy of killed-virus vaccines. In: The Theory and Practical Application of Adjuvants. Steward-Tull DES (Ed.). Wiley, Chichester, UK 37–50 (1995).
   Google Scholar
• Stanfield JP, Gall D, Bracken PM. Single-dose antenatal tetanus immunisation. Lancet1(7797), 215–219 (1973).
   PubMed Web of Science ®Google Scholar
• Veronesi R, Correa A, Alterio D. Single dose immunization against tetanus. Promising results in human trials. Rev. Inst. Med. Trop. Sao. Paulo12(1), 46–54 (1970).
   PubMedGoogle Scholar
• Klinguer C, Beck A, De-Lys P et al. Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens. Vaccine19(30), 4236–4244 (2001).
   PubMed Web of Science ®Google Scholar
• Lemoine D, Francotte M, Préat V. Nasal vaccines from fundamental concepts to vaccine development. STP Pharma. Sci.8(1), 5–18 (1998).
   Google Scholar
• Hilgers LA, Snippe H. DDA as an immunological adjuvant. Res. Immunol.143(5), 494–503 (1992).
   PubMedGoogle Scholar
• Shibata Y, Honda I, Justice JP, Van Scott MR, Nakamura RM, Myrvik QN. Th1 adjuvant N-acetyl-D-glucosamine polymer up-regulates Th1 immunity but down-regulates Th2 immunity against a mycobacterial protein (MPB-59) in interleukin-10-knockout and wild-type mice. Infect. Immun.69(10), 6123–6130 (2001).
   PubMed Web of Science ®Google Scholar
• Shibata Y, Metzger WJ, Myrvik QN. Chitin particle-induced cell-mediated immunity is inhibited by soluble mannan: mannose receptor-mediated phagocytosis initiates IL-12 production. J. Immunol.159(50), 2462–2467 (1997).
   PubMed Web of Science ®Google Scholar
• Strong P, Clark H, Reid K. Intranasal application of chitin microparticles down-regulates symptoms of allergic hypersensitivity to Dermatophagoides pteronyssinus and Aspergillus fumigatus in murine models of allergy. Clin. Exp. Allergy32(12), 1794–1800 (2002).
   PubMed Web of Science ®Google Scholar
• Hamajima K, Kojima Y, Matsui K et al. Chitin micro-particles (CMP): a useful adjuvant for inducing viral specific immunity when delivered intranasally with an HIV-DNA vaccine. Viral Immunol.16(4), 541–547 (2003).
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Ichinohe T, Strong P et al. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant. J. Med. Virol.75(1), 130–136 (2005).
   PubMed Web of Science ®Google Scholar
• Nishiyama A, Tsuji S, Yamashita M, Henriksen RA, Myrvik QN, Shibata Y.Phagocytosis of N-acetyl-D-glucosamine particles, a Th1 adjuvant, by RAW 264.7 cells results in MAPK activation and TNF-α, but not IL-10, production. Cell. Immunol.239(2), 103–112 (2006).
   PubMedGoogle Scholar
• Bivas-Benita M, van Meijgaarden KE, Franken KL et al. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine22(13–14), 1609–1615 (2004).
   PubMed Web of Science ®Google Scholar
• McNeela EA, O’Connor D, Jabbal-Gill I et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine19(9–10), 1188–1198 (2000).
   PubMed Web of Science ®Google Scholar
• Dodane V, Amin Khan M, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int. J. Pharm.182(1), 21–32 (1999).
   PubMed Web of Science ®Google Scholar
• Boonyo W, Junginger HE, Waranuch N, Polnok A, Pitaksuteepong T. Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration. J. Control Release121(3), 168–175 (2007).
   PubMed Web of Science ®Google Scholar
• Otterlei M, Varum KM, Ryan L, Espevik T. Characterization of binding and TNF-α-inducing ability of chitosans on monocytes: the involvement of CD14. Vaccine12(9), 825–832 (1994).
   PubMed Web of Science ®Google Scholar
• Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect. Immun.71(8), 4780–4788 (2003).
   PubMed Web of Science ®Google Scholar
• Duckett NS, Olmos S, Durrant DM, Metzger DW. Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain. Infect. Immun.73(4), 2306–2311 (2005).
   PubMedGoogle Scholar
• Luo Y, Yamada H, Chen X et al. Recombinant Mycobacterium bovis bacillus Calmette–Guerin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin. Exp. Immunol.137(1), 24–34 (2004).
   PubMed Web of Science ®Google Scholar
• Wang J, Zganiacz A, Xing Z. Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation. Vaccine20(23–24), 2887–2898 (2002).
   PubMed Web of Science ®Google Scholar
• Murray PJ, Aldovini A, Young RA. Manipulation and potentiation of antimycobacterial immunity using recombinant bacilli Calmette–Guerin strains that secrete cytokines. Proc. Natl Acad. Sci. USA94(3), 934–939 (1996).
   Google Scholar
• Staats HF, Bradney CP, Gwinn WM et al. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J. Immunol.167(9), 5386–5394 (2001).
   PubMed Web of Science ®Google Scholar
• Lillard JW Jr, Boyaka PN, Taub DD, McGhee JR. RANTES potentiates antigen-specific mucosal immune responses. J. Immunol.166(1), 162–169 (2001).
   PubMed Web of Science ®Google Scholar
• Kensil CR, Soltysik S, Wheeler DA, Wu JY. Structure/function studies on QS-21, a unique immunological adjuvant from Quillaja saponaria. Adv. Exp. Med. Biol.404(1): 165–172 (1996).
   PubMedGoogle Scholar
• Bangham AD, Horne RW, Glauert AM, Dingle JT, Lucy JA. Action of saponin on biological cell membranes. Nature196(4858), 952–955 (1962).
   PubMed Web of Science ®Google Scholar
• Sjolander A, Drane D, Maraskovsky E et al. Immune responses to ISCOM formulations in animal and primate models. Vaccine19(17–19), 2661–2665 (2001).
   PubMed Web of Science ®Google Scholar
• Smith RE, Donachie AM, Mowat AM. Immune stimulating complexes as mucosal vaccines. Immunol. Cell Biol.76(3) 263–269 (1998).
   PubMed Web of Science ®Google Scholar
• Scheerlinck JP, Gekas S, Yen HH et al. Local immune responses following nasal delivery of an adjuvanted influenza vaccine. Vaccine24(18), 3929–3936 (2006).
   PubMed Web of Science ®Google Scholar
• Hu KF, Elvander M, Merza M, Akerblom L, Brandenburg A, Morein B. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses. Clin. Exp. Immunol.113(2), 235–243 (1998).
   PubMed Web of Science ®Google Scholar
• Smith RE, Donachie AM, Grdic D, Lycke N, Mowat AM. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. J. Immunol.162(9), 5536–5546 (1999).
   PubMed Web of Science ®Google Scholar
• Cleland JL. Single-administration vaccines: controlled-release technology to mimic repeated immunizations. Trends Biotechnol.17(1), 25–29 (1999).
   PubMed Web of Science ®Google Scholar
• Yeh M, Chiang C. Inactive Vibrio cholerae whole-cell vaccine-loaded biodegradable microparticles: in vitro release and oral vaccination. J. Microencapsul.21(1), 91–106 (2004).
   PubMed Web of Science ®Google Scholar
• Vajdy M, O’Hagan DT. Microparticles for intranasal immunization. Adv. Drug. Deliv. Rev.51(1–3), 127–141 (2001).
   PubMed Web of Science ®Google Scholar
• Conway MA, Madrigal-Estebas L, McClean S, Brayden DJ, Mills KH. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine19(15–16), 1940–1950 (2001).
   PubMed Web of Science ®Google Scholar
• Carpenter ZK, Williamson ED, Eyles JE. Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu. J. Control Release104(1), 67–77 (2005).
   PubMed Web of Science ®Google Scholar
• Manocha M, Pal PC, Chitralekha KT et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine23(48–49), 5599–5617 (2005).
   PubMed Web of Science ®Google Scholar
• Patel GB, Zhou H, Ponce A, Chen W. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. Vaccine25(51), 8622–8636 (2007).
   PubMed Web of Science ®Google Scholar
• Baca-Estrada ME, Foldvari MM, Snider MM et al. Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses. Vaccine18(21), 2203–2211 (2000).
   PubMed Web of Science ®Google Scholar
• Harokopakis E, Hajishengallis G, Michalek SM. Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system. Infect. Immun.66(9), 4299–4304 (1998).
   PubMed Web of Science ®Google Scholar
• Rosada RS, de la Torre LG, Frantz FG et al. Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes. BMC Immunol.9, 38 (2008).
   PubMed Web of Science ®Google Scholar
• Schröder U, Svenson SB. Nasal and parenteral immuniizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants. Vaccine17(15–16), 2096–2103 (1999).
   PubMedGoogle Scholar
• Hamasur B, Haile M, Pawlowski A et al.Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine21(25–26), 4081–4093 (2003).
   PubMed Web of Science ®Google Scholar
• Haile M, Schröder U, Hamasur B et al. Immunization with heat-killed Mycobacterium bovis bacille Calmette–Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis. Vaccine22(11–12), 1498–1508 (2004).
   PubMed Web of Science ®Google Scholar
• Hiroi T, Iwatani K, Iijima H, Kodama S, Yanagita M, Kiyono H. Nasal immune system: distinctive Th0 and Th1/Th2 type environments in murine nasal-associated lymphoid tissues and nasal passage, respectively. Eur. J. Immunol.28(10), 3346–3353 (1998).
   PubMedGoogle Scholar
• Jones HP, Hodge LM, Fujihashi K, Kiyono H, McGhee JR, Simecka JW. The pulmonary environment promotes Th2 cell responses after nasal-pulmonary immunization with antigen alone, but Th1 responses are induced during instances of intense immune stimulation. J. Immunol.167(8), 4518–4526 (2001).
   PubMedGoogle Scholar
• Akbari O, Stock P, DeKruyff RH, Umetsu DT. Mucosal tolerance and immunity: regulating the development of allergic disease and asthma. Int. Arch. Allergy Immunol.130(2), 108–118 (2003).
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine25(30), 5467–5484 (2007).
   PubMed Web of Science ®Google Scholar
• Constant SL, Brogdon JL, Piggott DA et al. Resident lung antigen-presenting cells have the capacity to promote Th2 T cell differentiation in situ. J. Clin. Invest.110(10), 1441–1448 (2002).
   PubMed Web of Science ®Google Scholar